stockportfolio.pro
Stocks / IRWD vs NPCE
IRWD vs NPCE
Ironwood Pharmaceuticals, Inc. and NeuroPace, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Ironwood Pharmaceuticals, Inc. (IRWD) | NeuroPace, Inc. (NPCE) | |
|---|---|---|
| Market cap | $0.6B | $0.5B |
| Revenue (latest FY) | $296.15M | $99.99M |
| Net income (latest FY) | $24.02M | $-21.46M |
| Revenue growth (5y CAGR) | -5.3% | 19.4% |
| Net margin | 8.1% | -21.5% |
| Return on equity | -9.2% | -112.8% |
| P/E ratio | 5.7 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 6 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open IRWD — free Open NPCE — freeFrequently asked questions
Which is bigger, IRWD or NPCE?
Ironwood Pharmaceuticals, Inc. is larger by market capitalization — $0.6B versus $0.5B.
Which grows faster, IRWD or NPCE?
Over the last five fiscal years, NeuroPace, Inc. grew revenue faster — 19.4%/yr versus -5.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.